Oryzon Genomics Equity 2024

Oryzon Genomics Aktienanalyse

What does Oryzon Genomics do?

The company Oryzon Genomics SA is a biopharmaceutical company that was founded in 2000 in Barcelona, Spain. Since then, the company has gained a growing reputation for the development of innovative therapeutic approaches for serious diseases. Oryzon works on the development of epigenetic products that focus on molecular docking sites in the cell to modulate approved proteins and fragments. They use a unique technology called ORY-1001 to promote tumor apoptosis. The technology involves the use of epigenetic modulators to develop therapeutic approaches for certain types of cancer such as CLL and leukemia. Oryzon operates various divisions such as Research and Development, Intellectual Property, and Product Development. Within Research and Development, they work on the research and development of new technologies and products. They also have a portfolio of patented and potential patent applications in the field of epigenetics and products for the treatment of various types of cancer, neurodegenerative diseases such as Alzheimer's, and schizophrenia. The Intellectual Property division is responsible for all of Oryzon's patent rights. They review all of Oryzon's patents to ensure they meet the highest standards of patent law. The Product Development department helps the company in transferring newly developed products into effective and approved drugs. They also assist in the approval process by health authorities, particularly in the field of clinical trials. At the beginning of 2020, Oryzon announced that they will start a Phase 2 clinical trial for their product line ORY-2001 for the treatment of Alzheimer's patients. ORY-2001 is a selective histone deacetylase (HDAC) inhibitor aimed at slowing down the pathological process of Alzheimer's and other neurodegenerative diseases. This technology has the potential to improve the lives of millions of patients worldwide. In 2017, the company acquired WNT research from Inthera Bioscience SA, a biotechnology company focused on cancer treatment. The acquisition expanded Oryzon Genomics' portfolio to develop new innovative cancer therapies. The field of epigenetics is considered a rising and promising area in the medical industry. Oryzon Genomics has successfully positioned itself as a leading company in this field and continues to work on developing innovative solutions for the treatment of life-threatening diseases. The company remains a company to watch in the biopharmaceutical industry in the coming years. Oryzon Genomics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Oryzon Genomics's Equity

Oryzon Genomics's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Oryzon Genomics's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Oryzon Genomics's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Oryzon Genomics's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Oryzon Genomics’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Oryzon Genomics stock

What is the equity of Oryzon Genomics this year?

Oryzon Genomics has equity of 81.77 M EUR this year.

What was the equity of Oryzon Genomics compared to the previous year?

The equity of Oryzon Genomics has increased/decreased by 12.68% increased compared to the previous year.

What impact does a high equity have on investors of Oryzon Genomics?

A high equity is advantageous for investors of Oryzon Genomics as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Oryzon Genomics?

A low equity can be a risk for investors of Oryzon Genomics, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Oryzon Genomics affect the company?

An increase in equity of Oryzon Genomics can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Oryzon Genomics affect the company?

A reduction in equity of Oryzon Genomics can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Oryzon Genomics?

Some factors that can affect the equity of Oryzon Genomics include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Oryzon Genomics so important for investors?

The equity of Oryzon Genomics is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Oryzon Genomics take to change the equity?

To change equity, Oryzon Genomics can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Oryzon Genomics pay?

Over the past 12 months, Oryzon Genomics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Oryzon Genomics is expected to pay a dividend of 0 EUR.

What is the dividend yield of Oryzon Genomics?

The current dividend yield of Oryzon Genomics is .

When does Oryzon Genomics pay dividends?

Oryzon Genomics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Oryzon Genomics?

Oryzon Genomics paid dividends every year for the past 0 years.

What is the dividend of Oryzon Genomics?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Oryzon Genomics located?

Oryzon Genomics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Oryzon Genomics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Oryzon Genomics from 9/13/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 9/13/2024.

When did Oryzon Genomics pay the last dividend?

The last dividend was paid out on 9/13/2024.

What was the dividend of Oryzon Genomics in the year 2023?

In the year 2023, Oryzon Genomics distributed 0 EUR as dividends.

In which currency does Oryzon Genomics pay out the dividend?

The dividends of Oryzon Genomics are distributed in EUR.